This company listing is no longer active
Resumen de acción TBGN.F
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 3 riesgos adicionales
Competidores de Oxurion NV
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | €0.17 |
| 52 Week High | €2.00 |
| 52 Week Low | €0.17 |
| Beta | 0.38 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -91.54% |
| 3 Year Change | -94.33% |
| 5 Year Change | -97.28% |
| Change since IPO | -98.67% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| TBGN.F | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 0% | 4.7% | 0.7% |
| 1Y | -91.5% | 2.7% | 23.9% |
Rentabilidad vs. Industria: TBGN.F underperformed the US Biotechs industry which returned -8.9% over the past year.
Rentabilidad vs. Mercado: TBGN.F underperformed the US Market which returned -20.7% over the past year.
Volatilidad de los precios
| TBGN.F volatility | |
|---|---|
| TBGN.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: TBGN.F has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: Insufficient data to determine TBGN.F's volatility change over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1991 | 42 | Tom Graney | www.oxurion.com |
Resumen de fundamentos de Oxurion NV
| Estadísticas fundamentales de TBGN.F | |
|---|---|
| Capitalización bursátil | US$5.66m |
| Beneficios(TTM) | -US$30.82m |
| Ingresos (TTM) | US$1.19m |
4.7x
Ratio precio-ventas (PS)-0.2x
Ratio precio-beneficio (PE)¿Está TBGN.F sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de TBGN.F | |
|---|---|
| Ingresos | €1.13m |
| Coste de los ingresos | €612.00k |
| Beneficio bruto | €516.00k |
| Otros gastos | €29.67m |
| Beneficios | -€29.16m |
Últimos beneficios comunicados
Dec 31, 2021
Próxima fecha de beneficios
Mar 24, 2023
| Beneficios por acción (BPA) | -0.094 |
| Margen bruto | 45.74% |
| Margen de beneficio neto | -2,584.93% |
| Ratio deuda/patrimonio | -1,068.1% |
¿Cómo se ha desempeñado TBGN.F a largo plazo?
Ver rendimiento histórico y comparativa